© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Mark Fuerst | Authors
Articles
Many TNBC Patients Unnecessarily Opt for Mastectomy
June 16, 2017
The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.
Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
June 12, 2017
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.
Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
June 04, 2017
The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.